

# Jose Inciarte-Mundo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7047414/publications.pdf>

Version: 2024-02-01

23  
papers

357  
citations

758635

12  
h-index

839053

18  
g-index

24  
all docs

24  
docs citations

24  
times ranked

496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Treatment Patterns and Clinical Outcomes of Baricitinib in Rheumatoid Arthritis Patients in Spain: Results of a Multicenter, Observational Study in Routine Clinical Practice (The ORBIT-RA) Tj ETQq1 1 0.7843i14 rgBT7/Overloc	1.0	1
2	A multidisciplinary registry of patients with autoimmune and immune-mediated diseases with symptomatic COVID-19 from a single center. <i>Journal of Autoimmunity</i> , 2021, 117, 102580.	3.0	23
3	Comparable long-term outcomes between DAS28-ESR remission criteria and ACR/EULAR definitions in patients with established rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2021, 40, 2665-2672.	1.0	1
4	Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials. <i>Rheumatology and Therapy</i> , 2021, 8, 1435-1441.	1.1	15
5	Palindromic rheumatism: Evidence of four subtypes of palindromic-like arthritis based in either MEFV or rheumatoid factor/ACPA status. <i>Joint Bone Spine</i> , 2021, 88, 105235.	0.8	13
6	Patient Decision Aid (PDA) for Patients with Rheumatoid Arthritis Reduces Decisional Conflict and Improves Readiness for Treatment Decision Making. <i>Patient</i> , 2020, 13, 57-69.	1.1	17
7	Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2097813.	1.2	8
8	What Matters Most to Patients and Rheumatologists? A Discrete Choice Experiment in Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2020, 37, 1479-1495.	1.3	12
9	<p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 395-403.	0.7	10
10	Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. <i>Arthritis Research and Therapy</i> , 2018, 20, 275.	1.6	28
11	Reply. <i>Arthritis Care and Research</i> , 2017, 69, 606-607.	1.5	0
12	Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 303-309.	1.6	17
13	Musculoskeletal Involvement in Hereditary Hemochromatosis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 291-291.	0.5	1
14	Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 141.	1.6	17
15	Differing local and systemic inflammatory burden in polyarticular psoriatic arthritis and rheumatoid arthritis patients on anti-TNF treatment in clinical remission. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 74-79.	0.4	10
16	Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity. <i>Arthritis Research and Therapy</i> , 2016, 18, 160.	1.6	39
17	Serum Calprotectin Versus Acuteâ€Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors. <i>Arthritis Care and Research</i> , 2016, 68, 899-906.	1.5	42
18	Towards optimal cut-off trough levels of adalimumab and etanercept for a good therapeutic response in rheumatoid arthritis. Results of the INMUNOREMAR study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e42-e42.	0.5	24

#	ARTICLE	IF	CITATIONS
19	Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants. <i>Rheumatology</i> , 2015, 54, kev251.	0.9	26
20	Anti-citrullinated peptide/protein antibodies in Palindromic rheumatism: comment on the article by Emad Y et al.. <i>Clinical Rheumatology</i> , 2015, 34, 613-614.	1.0	0
21	Is There Subclinical Synovitis in Patients with Palindromic Rheumatism in the Intercritical Period? A Clinical and Ultrasonographic Study According to Anticitrullinated Protein Antibody Status. <i>Journal of Rheumatology</i> , 2014, 41, 1650-1655.	1.0	16
22	Reduction of Biological Agent Dose in Rheumatic Diseases: Descriptive Analysis of 153 Patients in Clinical Practice Conditions. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2014, 10, 10-16.	0.2	7
23	Reducci3n de dosis de terapias biol3gicas en enfermedades reumĀticas: anĀlisis descriptivo de 153 pacientes en condiciones de prĀctica clĀnica. <i>ReumatologĀa ClĀnica</i> , 2014, 10, 10-16.	0.2	22